

Oregon Prescription Drug Monitoring Program 2022 1st Quarter Report

Percentage change evaluated relative to 1st Quarter, 2021

healthoregon.org/pdmp



Summary

- Registration has increased over the last year for several user groups (MD/PA/DO, +1.5%; NP/CNS-PP, +9.8%; NO, +9.3%) but decreased for all others (Table 4).
- Integrated queries have slightly increased 2.8% while web queries have increased by 9.3% from the 1st quarter of 2021 (Table 1). Integrated reports viewed have seen a large increase of 30.6% indicating increased usage of the PDMP.
- The percentage of enrolled prescribers who queried the PDMP has stayed consistent compared to the first quarter of 2021 (Table 3).
- Overall, prescriptions of controlled substances have decreased -1.2% with gabapentin moving up to be the top prescription. Additionally, amphetamine prescriptions are up 19.7% and methylphenidate prescriptions increased 13.5% (Table 5).




Table 1. PDMP Queries Summary Statistics: January-March, 2022

User Type	Web Portal		Gateway Integration			
	Queries	% Change ¹	Automated Queries	% Change ¹	Reports Viewed	% Change ¹
Healthcare providers	88,567	10.0%	6,019,193	0.6%	1,024,819	44.1%
Pharmacies	70,547	22.3%	1,159,275	15.7%	583,416	12.3%
Delegates	156,241	3.9%	-	-	-	-
Total of all users²	315,499	9.3%	7,178,468	2.8%	1,608,235	30.6%

- Web portal queries have increased from the same quarter last year across all user groups, with the largest increase seen in queries by pharmacies.
- The number of integrated automated queries has increased over the same quarter last year. Integrated reports viewed has increased significantly over the last year indicating that providers are increasingly using the PDMP to check patient records.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

Table 2. Special Requests: January-March, 2022

Measure	Count
Patient Records	8
Healthcare Board	77
Law Enforcement	10
Special Requests Total	95

- 95 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

¹ Percentage change figures evaluated relative to the same time period during the prior year.

² Query data drawn from Appriss AWARxE web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2022 1st Quarter Report

Percentage change evaluated relative to 1st Quarter, 2021

healthoregon.org/pdmp



Table 3. PDMP Enrollment and System Use¹: January-March, 2022

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
All Prescribers (by DEA)	18,651	15,643 / 83.9%	5,261 / 33.6%	11,722 / 74.9%	12,960 / 82.8 %
Top 4K Prescribers	4,000	3,869 / 96.7%	2,096 / 54.2%	3,441 / 88.9%	3,696 / 95.5 %
Top 2K Prescribers	2,000	1,959 / 98.0%	1,154 / 58.9%	1,762 / 89.9%	1,882 / 96.1 %

- During the 1st quarter of 2022 there were 18,651 prescribers who wrote prescriptions for controlled substances in Oregon.
- At the close of the 1st quarter, 82.8% of enrolled prescribers queried the system; 95.5% of the top 4,000 prescribers; 96.1 % of the top 2,000 prescribers through the web portal or integration.
- The percentage of enrolled prescribers who queried the system has slightly increased since the first quarter of 2021, when 82.0% of enrolled prescribers submitted queries.

Table 4. PDMP Query by Clinical User Group¹: January-March, 2022

Discipline	Total User Accounts (by DEA)	% Change ²	Web Users ^{3,4}	% Change ²	Integrated Users	% Change ²
MD/PA/DO	17,793	+1.5%	1,686	-7.5%	13,734	+7.7%
NP/CNS-PP	4,451	+9.8%	992	1.6%	3,293	+12.0%
RPh	3,260	-1.4%	1,394	-8.2%	423	+19.1%
Delegates	3,266	-2.3%	1,696	-14.2%	-	-
DDS/DMD	2,732	-0.1%	403	-0.7%	237	+4.6%
ND	613	+8.3%	147	-1.4%	450	+11.3%

- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing, while integrated users are increasing.

¹ Prescriber counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.

² Percentage change figures evaluated relative to the same time period during the prior year.

³ Query data drawn from Appriss AWARxE web portal and the PMPi Gateway.

⁴ Users that have submitted a query this quarter

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Table 5. Top Prescriptions: January-March, 2022

Drug	# of Rx	% of all Rx	% Change ¹
All	1,612,089	100.0%	- 1.2%
Gabapentin	226,103	14.0%	0.5%
Hydrocodone	221,068	13.7%	-7.4%
Oxycodone	215,335	13.4%	-3.3%
Amphetamine	191,476	11.9%	+19.7%
Methylphenidate	81,164	5.0%	+13.5%
Lorazepam	80,543	5.0%	-4.6%
Tramadol	76,015	4.7%	-6.6%
Zolpidem	63,017	3.9%	-5.7%
Alprazolam	58,975	3.7%	-4.4%
Clonazepam	57,037	3.5%	-5.0%

- The number of prescriptions for gabapentin increased relative to the same quarter last year, while hydrocodone decreased.
- Prescriptions for commonly prescribed benzodiazepines decreased (i.e., lorazepam, alprazolam, clonazepam), while prescriptions for the stimulants amphetamine and methylphenidate increased by 19.7% and 13.5% relative to the same quarter last year.
- Gabapentin is the top prescribed drug (14% of all prescriptions) in the PDMP. The addition of gabapentin as a PDMP covered substance was effective as of January 1st, 2020.

Table 6. Prescriptions for Buprenorphine and Naloxone: January-March, 2022

Drug	# of Rx	% of all Rx	% Change ¹
Buprenorphine/Naloxone	42,910	2.7%	-2.0%
Buprenorphine	22,658	1.4%	+6.6%
Naloxone	5,979	0.4%	+16.6%

- Prescriptions for buprenorphine and naloxone have increased while prescriptions for buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, pdmp.research@state.or.us

¹ Percentage change figures evaluated relative to the same time period during the prior year.